|Day's range||2.9400 - 4.1300|
Moderna (NASDAQ: MRNA) helped some investors make a fortune over the past few years. The stock has climbed more than 400% since March 2020 -- that's when the company's coronavirus vaccine program gained traction. Recently, though, investors have worried about Moderna's post-pandemic revenue, and that's weighed on share performance.
Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.
Key Insights Given the large stake in the stock by institutions, Moderna's stock price might be vulnerable to their...